MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis
Key facts
- Where
- Oslo, NorwaySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT07444047, who can take part
Where in Norway
- Oslo University HospitalOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital
- Trial code
- NCT07444047
- Record updated
- 1 June 2026
- Original description
This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS). In older individuals with MS, white matter changes seen on MRI may be related to MS or to other types of white matter changes, most commonly age-related changes or chronic small vessel disease. These conditions can appear similar on conventional MRI scans, making interpretation challenging.Read full original descriptionShow less
Quantitative Susceptibility Mapping for Lesion Differentiation in Aging Multiple Sclerosis
This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS). In older individuals with MS, white matter changes seen on MRI may be related to MS or to other types of white matter changes, most commonly age-related changes or chronic small vessel disease. These conditions can appear similar on conventional MRI scans, making interpretation challenging.
Participants will undergo routine clinical MRI, including a short additional QSM sequence, as well as brief cognitive and physical assessments. A comparison group with cerebral small vessel disease will also be included.
The goal of the study is to determine whether QSM can provide more precise lesion characterization and support more accurate clinical interpretation of MRI findings in older patients with MS.
Inclusion: Age 50-70 years; Clinically confirmed diagnosis of multiple sclerosis; Participation in the AgeMS study at Oslo University Hospital; Age 50-80 years; Radiological evidence of hypertensive small vessel disease on MRI; Good clinical recovery following transient ischemic attack (TIA), minor stroke, or stroke mimic diagnosis.
Exclusion: Severe psychiatric comorbidity; Severe psychiatric comorbidity; MRI contraindications; Major functional disability unrelated to MS or CSVD; MRI contraindications; Probable or definite cerebral amyloid angiopathy according to Boston criteria 2.0; Genetic or inflammatory vasculopathies; Persistent neurological deficits; Major functional disability unrelated to CSVD.